Speaking of a Catch-22 on pricing…JNJ and Bayer have one with Xarelto. Do they price it sky high for the relatively short duration of VTE prevention following orthopedic surgery, or do they price it much lower to garner off-label (and eventually on-label) business at the expense of Pradaxa/Eliquis in AF? There’s a huge expanse between these two poles.
Market Data 
Markets 
AI
